# Another Option for Rare Benign Soft-Tissue Tumor Wins FDA Approval

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/hematologyoncology/othercancers/123817) · 2026-11-10 · Medicine
Page: https://themorning.science/story/another-option-for-rare-benign-soft-tissue-tumor-wins-fda-approval-5ddc223e2ccdd76c
Kind: other · Impact: medium

## In brief

- The FDA approved the small-molecule inhibitor pimicotinib, sold as Pimjetmi, for selected patients with symptomatic tenosynovial giant cell tumour (TGCT).
- The approval covers patients with TGCT who are at high surgical risk.
- Pimicotinib is an oral selective inhibitor of a colony stimulating factor pathway, according to MedPage Today.

## Why it matters

TGCT is a rare, usually benign soft-tissue tumour, and this approval adds an oral drug option for patients for whom surgery carries high risk.

## Coverage

- [Another Option for Rare Benign Soft-Tissue Tumor Wins FDA Approval](https://www.medpagetoday.com/hematologyoncology/othercancers/123817) — MedPageToday.com - medical news for physicians, 2026-11-10

Tags: oncology, fda, drug-approval, rare-disease, tgct

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science